Adult Growth Hormone Replacement: Lessons Learned and Future Direction

R. D. Murray and S. M. Shalet

Department of Endocrinology, Christie Hospital, Manchester, United Kingdom M20 4BX

Address all correspondence and requests for reprints to: Prof. S. M. Shalet, Department of Endocrinology, Christie Hospital, National Health Service Trust, Wilmslow Road, Manchester, United Kingdom M20 4BX. E-mail: stephen.m.shalet{at}man.ac.uk.

After publication of the first two randomized placebo-controlled studies of GH replacement in GH-deficient adults in 1989 (1, 2), it became clear that GH plays an important role in the maintenance of physiological processes within the adult. The beneficial effect of GH on body composition, serum lipids, and quality of life in these two studies has been confirmed in a number of similarly designed, placebo-controlled studies. Further evidence indicating that GH may be even more important in the adult than suggested by these initial studies is derived from several large retrospective cohort studies, which demonstrated an increased standardized mortality rate in hypopituitary adults with untreated GH deficiency, in the region of 1.8, compared with the general population (3, 4). Further retrospective cohort studies have also indicated an increased prevalence of fractures in GH-deficient hypopituitary adults (5). In 1996, on the basis of the beneficial effects observed in the above-described, randomized, placebo-controlled studies and the possibility that adult GH replacement therapy would reverse the reported increases in mortality and fracture rates of hypopituitary adults, GH received a license for use as replacement therapy in the hypopituitary adult.

In adult hypopituitarism all of the evidence for the beneficial effect of GH replacement had been obtained from placebo-controlled studies using GH dosing regimens based on weight derived from experience in the pediatric setting. As a consequence, side effects were common, necessitating withdrawal of patients from the study or significant dose reductions in a high proportion of the study population. Unsurprisingly, serum IGF-I values were above the age-related reference range in many patients, bringing into question whether the observed beneficial effects of GH were the result of replacement therapy or of pharmacological intervention. In retrospect, the use of weight-based dosing regimens was counterintuitive, given that we know that spontaneous GH secretion is reduced with increasing body mass index, is approximately 3-fold greater in females compared with males, and is reduced by approximately 14%/decade of adult life (6). Thus, when using a weight-based dosing regimen, complex algorithms would be required to compensate for these given variables.

In 1998, the Growth Hormone Research Society issued guidelines for the diagnosis and treatment of GH-deficient adults (7). It was recommended that adult GH replacement be commenced at a low dose and individually optimized according to the clinical and biochemical responses. The age-adjusted IGF-I is generally accepted as the best biochemical marker to allow monitoring of the GH dose and thus prevent overreplacement of GH in an individual. Despite these guidelines the medical literature contains few studies of adult GH replacement in which the GH dose has been slowly increased from the outset of the study according to the serum IGF-I level and the maintenance GH dose individually optimized.

Establishing the benefit of GH replacement in the adult using weight-based dosing regimens made it ethically difficult to perform further randomized, placebo-controlled studies using an individually optimized GH dosing regimen. Such studies would deny a proportion of the patients a therapy with which benefits had purportedly been substantiated. Thus, there are no randomized, double-blind, placebo-controlled studies using an individually optimized GH dosing regimen. At first glance, several placebo-controlled studies appear to reflect individualized GH dosing; in these studies, however, GH replacement has been initiated using a weight-based regimen with dose reduction to individualize the GH dose according to the serum IGF-I level only occurring later (8, 9, 10). Thus, it can be argued that the observed beneficial effects result from the earlier higher GH doses consequent on the weight-based dosing regimen. Reports of the possible benefits of this more physiological GH replacement regimen are thus dependent on audit of practice studies and therefore are subject to criticism associated with this study design (11, 12, 13, 14, 15, 16); these latter studies have confirmed that GH has a beneficial effect on body composition, serum lipids, bone mineral density, and quality of life. In general, however, the beneficial changes observed with individualized GH dosing, quality of life being the one exception, have been of lesser magnitude than in previous weight-based replacement regimens. Furthermore, interpretation of the results is potentially confounded by the placebo effect and regression toward the mean, which are difficult to quantify. Nonetheless, individually optimized GH replacement has been shown to produce significant improvements in quality of life using both generic and disease-specific questionnaires, a reduction in total and low density lipoprotein cholesterol in the region of 0.4 mmol, a 2% fall in body fat mass with an increase in lean body mass of similar magnitude, and a 3.5% increase in lumbar spine bone mineral density (BMD) with 18-month replacement.

An important observation from studies of adult GH replacement is that the degree of improvement in many of the biological end points is proportional to the degree of deviation from normal at baseline. Thus, the greatest improvement in quality of life, serum lipids, and BMD has been shown to occur in patients with the most impaired quality of life, the highest serum lipid values, and the lowest BMD, respectively. In fact, a significant proportion of patients with GH deficiency experience no adverse effect on certain GH-dependent biological end points, for instance quality of life or BMD (17). In the absence of evidence that GH replacement normalizes or reduces mortality risk and in a health system with finite resources, GH replacement should be reserved for those patients with the greatest morbidity pretreatment. Furthermore, the inclusion of patients with no significant morbidity at baseline in studies of GH replacement will dilute any beneficial effect observed within the cohort of GH- deficient patients with significant morbidity (9).

Thus, after the initial studies of GH replacement in adult hypopituitarism in 1989 we now understand that this hormone requires individualization of the dose, using the serum IGF-I level to avoid overreplacement and GH-related side effects. Furthermore, significant morbidity seems to be restricted to a proportion of patients with GH deficiency. The benefit of GH replacement using a titrated individualized GH regimen in patients selected on the basis of significant morbidity at baseline has not been studied in the setting of randomized placebo-controlled studies. To build on the solid groundwork of the last 13 yr, consolidate our knowledge, and define, beyond doubt, the degree of benefit GH replacement has on the many biological end points, these further placebo-controlled studies of GH replacement in the hypopituitary adult must be performed.

Acknowledgments

Footnotes

Abbreviation: BMD, Bone mineral density.

Received March 19, 2002.

Accepted July 22, 2002.

References

  1. Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Ingemann Hansen T, Skakkebaek NE, Christiansen JS 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1:1221–1225[Medline]
  2. Salomon F, Cuneo RC, Hesp R, Sonksen PH 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321:1797–1803[Abstract]
  3. Rosen T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288[Medline]
  4. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425–431[CrossRef][Medline]
  5. Rosen T, Wilhelmsen L, Landin Wilhelmsen K, Lappas G, Bengtsson BA 1997 Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 137:240–245[Medline]
  6. Iranmanesh A, Lizarralde G, Veldhuis JD 1991 Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 73:1081–1088[Abstract]
  7. Growth-Hormone-Research-Society 1998 Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 83:379–381[Abstract/Free Full Text]
  8. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A 1996 Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 125:883–890[Abstract/Free Full Text]
  9. Baum HBA, Katznelson L, Sherman JC, Biller BMK, Hayden DL, Schoenfeld DA, Cannistraro KE, Klibanski A 1998 Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 83:3184–3189[Abstract/Free Full Text]
  10. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A 2000 Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111–122[Abstract/Free Full Text]
  11. Drake WM, Coyte D, Camacho Hubner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP 1998 Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 83:3913–3919[Abstract/Free Full Text]
  12. Murray RD, Skillicorn CJ, Howell SJ, Lissett CA, Rahim A, Shalet SM 1999 Dose titration and patient selection increases the efficacy of GH replacement in GHD adults. Clin Endocrinol (Oxf) 50:749–757[CrossRef][Medline]
  13. Murray RD, Adams JE, Smethurst LE, Shalet SM 2002 Spinal irradiation impairs the osteo-anabolic effects of low-dose growth hormone replacement in adults with childhood-onset GH deficiency. Clin Endocrinol (Oxf) 56: 169–174
  14. Florakis D, Hung V, Kaltsas G, Coyte D, Jenkins PJ, Chew SL, Grossman AB, Besser GM, Monson JP 2000 Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol (Oxf) 53:453–459[CrossRef][Medline]
  15. Ahmad AM, Hopkins MT, Thomas J, Ibrahim H, Fraser WD, Vora JP 2001 Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clin Endocrinol (Oxf) 54:709–717[CrossRef][Medline]
  16. Murray RD, Wieringa GE, Lissett CA, Darzy KH, Smethurst LE, Shalet SM 2002 Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome. Clin Endocrinol (Oxf) 56:525–532[CrossRef][Medline]
  17. Holmes SJ, Shalet SM 1995 Factors influencing the desire for long-term growth hormone replacement in adults. Clin Endocrinol (Oxf) 43:151–157[Medline]